The potential nephrotoxic effects of intensity modulated radiotherapy delivered to the para-aortic area of women with gynecologic malignancies: Preliminary results

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 29, Issue 3, 2006, Pages 281-289

  Varlotto, John M ^a   Gerszten, Kristina ^b   Heron, Dwight E ^b   Comerci, John ^b   Gautam, Shiva ^a   Selvaraj, Raj ^b   Lalonde, Ron ^c   Chura, Justin C ^d  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c D3 Radiation Planning   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Gynecologic malignancies; Intensity modulated radiotherapy; Para aortic irradiation

Indexed keywords

CISPLATIN; CREATININE; ANTINEOPLASTIC AGENT;

ADULT; AGE; AGED; ARTICLE; CLINICAL ARTICLE; CREATININE CLEARANCE; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; GYNECOLOGIC CANCER; HUMAN; HYDRONEPHROSIS; INTENSITY MODULATED RADIATION THERAPY; KIDNEY FUNCTION; NEPHROTOXICITY; PARAAORTIC LYMPH NODE; RISK FACTOR; STATISTICAL SIGNIFICANCE; ABDOMINAL AORTA; CLINICAL TRIAL; FEMALE GENITAL TRACT TUMOR; KIDNEY DISEASE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; RADIATION DOSE FRACTIONATION; RADIATION EXPOSURE; RADIATION INJURY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; AORTA, ABDOMINAL; CISPLATIN; CREATININE; DOSE FRACTIONATION; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; KIDNEY DISEASES; MIDDLE AGED; RADIATION INJURIES;

EID: 33744991717     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/01.coc.0000217828.95729.b5     Document Type: Article

References (48)

1. Rotman M, Pajak TF, Choi K, et al. Prophylactic extended-field irradiation of para-aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. Ten-year treatment results of RTOG 79-20. JAMA. 1995;274:387-393.
2. Haie C, Pejovic MH, Gerbault A, et al. Is prophylactic para-aortic irradiation worthwhile in the treatment of advanced cervical carcinoma? Results of a controlled clinical trial of the EORTC Radiotherapy Group. Radiother Oncol. 1988;11:101-112.
3. Eifel PJ, Winter K, Morris M, et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of Radiation Therapy Oncology Group Trial 90-01. J Clin Oncol. 2004;22:872-880.
4. Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340:1144-1153.
5. Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 1999;340:1154-1161.
6. Peters WA, Liu PY, Barrett RJ, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000;18:1606-1613.
7. Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stages IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group Study. J Clin Oncol. 1999;5:1339-1348.
8. Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999;340:1137-1143.
9. Colonello K, Gerszten K, Heron DE, Fitian ID, Comerci J. Feasibility of concurrent cisplatin and extended field radiation therapy (EFRT) using intensity modulated radiotherapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys. 2004;60(Suppl. 1):S301(Abstr 1074).
10. Kunkler PB, Farr RF, Luxton RW. The limit of renal tolerance to X-rays. Br J Radiol. 1952;25:190-201.
11. Willett CG, Tepper JE, Orlow BA, et al. Renal complications secondary to the treatment of upper abdominal malignancies. Int J Radit Oncol Biol Phys. 1986;12:1601-1604.
12. Dewit L, Anninga JK, Hoefnagel CA, et al. Radiation injury in the human kidney: a prospective analysis using specific scintigraphic and biochemical endpoints. Int J Radiat Oncol Biol Phys. 1990;19:977-983.
13. Burman C, Kutcher GJ, Emami G, et al. Fitting of normal tissue tolerance to an analytic function. Int J Radiat Oncol Biol Phys. 1991;21:123-135.
14. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissues to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109-122.
15. Cassady JR. Clinical radiation nephropathy. Int J Radiat Oncol Biol Phys. 1995;31:1249-1256.
16. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
17. Shiraiwa M, Joja I, Asakawa T, et al. Cervical carcinoma: efficacy of thin-section oblique axial T2-weighted images for evaluating parametrial invasion. Abdominal Imaging. 1999;24:514.
18. Ozsarlak O, Tjalma W, Schepens E, et al. The correlation of preoperative CT, MRI imaging, and clinical staging (FIGO) with histopathology findings in primary cervical carcinoma. Eur Radiol. 2003;13:2338-2345.
19. Heron DE, Gerszten K, Selvaraj RN, et al. Conventional 3D conformal versus intensity-modulated radiotherapy for the adjuvant treatment of gynecologic malignancies: a comparative dosimetric study of dose-volume histograms. Gynecol Oncol. 2003;91:39-45.
20. Fowler JF. The Linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol. 1989;62:679-94.
21. Cohen EP, Robbins M. Radiation nephropathy. Semin Nephrol. 2003;23:486-499.
22. Thompson PL, Mackay IR, Robson GSM, et al. Late radiation nephritis after gastric X-irradiation for peptic ulcer. Q J Med New Series. 1971;40:145-157.
23. Asscher AW. The delayed effects of renal irradiation. Clin Radiol. 1964;15:320-325.
24. Kunkler PB, Farr RF, Luxton RW. The limit of renal Tolerance to X-rays. Br J Radiol. 1952;25:190.
25. O'Donoghue J. Relevance of external beam dose-response relationships to the kidney toxicity associated with radionuclide therapy. Cancer Biother Radiopharm. 2004;19:378-387.
26. Irwin C, Fyles A, Wong CS, et al. Late renal function following whole abdominal irradiation. Radiother Oncol. 1996;38:257-261.
27. Maor MH, North LB, Cabanillas FF, et al. Outcomes of high-dose unilateral kidney irradiation in patients with gastric lymphoma. Int J Radiat Oncol Biol Phys. 1998;41:647-650.
28. Kost S, Dorr W, Keinert K, et al. Effect of dose and dose distribution in damage to the kidney following abdominal radiotherapy. Int J Radiat Biol. 2002;78:695-702.
29. Lawton CA, Barber-Derus SW, Murray KJ, et al. Influence of renal shielding on the incidence of renal dysfunction associated with T-lymphocyte deplete bone marrow transplantation in adult patients. Int J Radiat Oncol Biol Phys. 1992;23:681-686.
30. Lawton CA, Cohen EP, Murray KJ, et al. Long-term results of selective renal shielding in patients undergoing total body irradiation in preparation for bone marrow transplantation. Bone Marrow Transplant. 1997;20:1069-1074.
31. Juckett MB, Cohen EP, Keever-Taylor CA, et al. Loss of renal function following bone marrow transplantation: an analysis of angiotensin converting enzyme D/I polymorphism and other clinical risk factors. Bone Marrow Transplant. 2001;27:451-456.
32. Miralbell R, Bieri S, Mermillod B, et al. Renal toxicity after allogeneic bone marrow transplantation: the combined effects of total-body irradiation and graft-versus-host disease. J Clin Oncol. 1996;14:579-585.
33. Borg M, Hughes T, Horvath N, et al. Renal toxicity after total body irradiation. Int J Radiat Oncol Biol Phys. 2002;54:1165-1173.
34. Tarbell NJ, Guinan EC, Niemeyer C, et al. Late onset of renal dysfunction in survivors of bone marrow transplantation. Int J Radiat Oncol Biol Phys. 1988;15:99-104.
35. Tarbell NJ, Guinan EC, Chin L, et al. Renal insufficiency after total body irradiation for pediatric bone marrow transplantation. Radiother Oncol. 1990;18:139-142.
36. Miralbell R, Sancho G, Bieri S, et al. Renal insufficiency in patients with hematologic malignancies undergoing total body irradiation and bone marrow transplantation: a prospective assessment. Int J Radiat Oncol Biol Phys. 2004;58:809-816.
37. Cohen EP, Hussain S, Moulder JE. Successful treatment of radiation nephropathy with angiotensin II blockade. Int J Radiat Oncol Biol Phys. 2003;55:190-193.
38. Ward WF, Lin PP, Wong PS, et al. Radiation pneumonitis in rats and its modification by the angiotensin-converting enzyme inhibitor captopril evaluated by high resolution computed tomography. Radiat Res. 1993;135:81-87.
39. Molteni A, Moulder JE, Cohen EP, et al. Control of radiation-induced pneumopathy and lung fibrosis by angiotensin converting enzyme inhibitors and an angiotensin II type1 receptor blocker. Int J Radiat Oncol Biol Phys. 2000;76:523-532.
40. Martin M, Lefaix J, Delanian S. TGF-beta1 and radiation fibrosis: a master switch and a specific therapeutic target? Int J Radiat Oncol Biol Phys. 2000;47:277-290.
41. Wang J, Robbins MEC. Radiation-induced alteration of rat mesangial cell transforming growth factor-beta and expression of the genes associated with the extrcellular matrix. Radiat Res. 1996;146:561-568.
42. Zhao W, O'Malley Y, Wei S, et al. Irradiation of rat tubule epithelial cells alters the expression of gene products associated with the synthesis and degradation of extracellular matrix. Int J Radiat Biol. 2000;76:391-402.
43. Datta PK, Moulder JE, Fish BL, et al. TGF-B1 production in radiation nephropathy: role of angiotensin II. Int J Radiat Biol. 1999;75:473-479.
44. Cohen EP, Robbins M. Radiation nephropathy. Semin Nephrol. 2003;23:486-499.
45. Moulder JE, Fish BL, Cohen EP. Non-continuous use of angiotensin converting enzyme inhibitors in the treatment of experimental bone marrow transplant nephropathy. Bone Marrow Transplant. 1997;19:729-735.
46. Smith LG III, Pearse HD. The Kidney. In: Cox JD, Ang KK, eds. Radiation Oncology: Rationale, Technique, Results, ed. 8. St. Louis, MI: CV Mosby; 2002:559-574.
47. Zagars GK, Ballo MT, Lee AK, et al. Mortality after cure of testicular seminoma. J Clin Oncol. 2004;22:640-647.
48. Randall ME, Filiaci VL, Muss H, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Group Study. J Clin Oncol. 24:36-44.